Efficacy of Levetiracetam in the treatment of spasticity in MS: a rano
Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Levetiracetam
Synaptic vesicle glycoprotein 2A modulator|Voltage-gated N-type calcium channel alpha-1B subunit blocker
What it measured
Main measures
improvement of spasticity scores
Spasticity
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: clinical definite MS Exclusion: known intolerance towards Levetiracetam
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Reduction of spasticity measrued in clinical scores (Ashworth an Penn scale)
Loading reviews and guidelines…
Related trials
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiot
Phase 3 · Not yet recruiting
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
- Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Me
Phase 3 · Stopped early
Stopped
- Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinica
Phase 3 · Completed
Missed its main goal
- Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Ther
Phase 3 · Stopped early
Stopped
History
- Status changed from Ongoing to Status unknown
- Result signal changed from Ongoing to Status unknown
Started
Sept 2006